论文部分内容阅读
目的评价１３１Ｉ单克隆抗体ｃｈＴＮＴ与肝肿瘤的亲和性，以了解其用于肝肿瘤定位诊断和导向治疗的可能性。方法荷人肝癌裸鼠动物模型腹腔注射５５５ＭＢｑ１３１ＩｃｈＴＮＴ后１、２、３、５、７天，分别作放射免疫显像，并逐日分组杀死，行组织分布测定，并与１３１Ｉ对照组比较。结果实验组注射标记抗体后１天肿瘤组织清晰显影，并持续显示至实验结束。瘤体内放射性维持相对稳定水平，１３１ＩｃｈＴＮＴ在肝癌组织内的有效半减期为６０±１６天。其他脏器组织放射性浓聚少，并逐渐消失。第７天Ｔ／ＮＴ比值达１０６７。结论１３１ＩｃｈＴＮＴ具有导向肝肿瘤的特性，为用于肝癌放射免疫显像和导向治疗提供了依据。
Objective To evaluate the affinity of 131I monoclonal antibody (chTNT) and liver tumor to understand its potential for localization diagnosis and targeted therapy in liver tumors. Methods The nude mice bearing human hepatocellular carcinoma were injected intraperitoneally with 5 55MBq131IchTNT 5 55MBq131IchTNT and radioimmunoimaging was performed respectively. The mice were sacrificed on a daily basis. The tissue distribution was measured and compared with 131I control group Compare Results In the experimental group, the tumor tissue was clearly developed one day after the labeled antibody was injected, and continued to be displayed until the end of the experiment. Tumor in vivo to maintain a relatively stable level of radioactivity, 131I chTNT in liver cancer tissue half-effective period of 6 ± 1 6 days. Other organs and tissues less concentrated radioactivity, and gradually disappear. On day 7, the T / NT ratio reached 10.67. Conclusion 131I chTNT has the characteristics of liver-oriented tumors for the liver cancer radioimmunoimaging and guidance provided the basis.